[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2023000216A1 - Anticuerpos anti-abeta - Google Patents

Anticuerpos anti-abeta

Info

Publication number
CL2023000216A1
CL2023000216A1 CL2023000216A CL2023000216A CL2023000216A1 CL 2023000216 A1 CL2023000216 A1 CL 2023000216A1 CL 2023000216 A CL2023000216 A CL 2023000216A CL 2023000216 A CL2023000216 A CL 2023000216A CL 2023000216 A1 CL2023000216 A1 CL 2023000216A1
Authority
CL
Chile
Prior art keywords
antibodies
abeta antibodies
methods
abeta
bind
Prior art date
Application number
CL2023000216A
Other languages
English (en)
Inventor
Barbour Robin
Zago Wagner
S Nijjar Tarlochan
Skov Michael
Govindarajan Sridhar
Purcell Tom
Welch Mark
Bard Frédérique
Original Assignee
Othair Prothena Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Othair Prothena Ltd filed Critical Othair Prothena Ltd
Publication of CL2023000216A1 publication Critical patent/CL2023000216A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan anticuerpos que se unen al péptido beta-amiloide humano, métodos para detectar, medir y tratar trastornos amiloidogénicos con dichos anticuerpos, composiciones farmacéuticas que comprenden los anticuerpos y métodos de elaboración.
CL2023000216A 2020-07-23 2023-01-23 Anticuerpos anti-abeta CL2023000216A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063055813P 2020-07-23 2020-07-23
US202063086589P 2020-10-01 2020-10-01
US202163187379P 2021-05-11 2021-05-11
US202163219611P 2021-07-08 2021-07-08

Publications (1)

Publication Number Publication Date
CL2023000216A1 true CL2023000216A1 (es) 2023-10-20

Family

ID=79728984

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2023000216A CL2023000216A1 (es) 2020-07-23 2023-01-23 Anticuerpos anti-abeta
CL2024000953A CL2024000953A1 (es) 2020-07-23 2024-04-01 Anticuerpos anti-abeta
CL2025000063A CL2025000063A1 (es) 2020-07-23 2025-01-10 Anticuerpos anti-abeta

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2024000953A CL2024000953A1 (es) 2020-07-23 2024-04-01 Anticuerpos anti-abeta
CL2025000063A CL2025000063A1 (es) 2020-07-23 2025-01-10 Anticuerpos anti-abeta

Country Status (15)

Country Link
US (8) US20220049009A1 (es)
EP (1) EP4185612A4 (es)
JP (1) JP2023535024A (es)
KR (1) KR20230039734A (es)
CN (1) CN116348487A (es)
AU (1) AU2021310926A1 (es)
BR (1) BR112023001061A2 (es)
CA (1) CA3186614A1 (es)
CL (3) CL2023000216A1 (es)
IL (1) IL300059A (es)
MX (1) MX2023000949A (es)
PH (1) PH12023550178A1 (es)
TW (1) TW202216760A (es)
UY (1) UY39337A (es)
WO (1) WO2022020680A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116348487A (zh) 2020-07-23 2023-06-27 欧萨尔普罗席纳有限公司 抗淀粉样β抗体
AU2024209632A1 (en) 2023-01-20 2025-05-08 Mabwell Therapeutics, Inc. ANTI-AMYLOID β PROTOFIBRIL/OLIGOMER ANTIBODIES AND USES THEREOF
TW202434629A (zh) * 2023-01-26 2024-09-01 愛爾蘭商歐薩爾普羅席納有限公司 以抗類澱粉β (ABETA)抗體治療神經病症之方法
WO2025015254A2 (en) * 2023-07-12 2025-01-16 Lloyd Tran Therapeutic agent composition and method of use of combination therapy for treatment of mild cognitive impairment

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3003097A (en) 1958-07-17 1961-10-03 Gen Electric Sequence control system for timing motor
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
ATE420178T1 (de) 1992-08-21 2009-01-15 Univ Bruxelles Immunoglobuline ohne leichtkette
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6518011B1 (en) 1999-01-13 2003-02-11 Bristol-Myers Squibb Company Method for screening compounds to identify beta-amyloid production modulators
US7629311B2 (en) 1999-02-24 2009-12-08 Edward Lewis Tobinick Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
KR100767146B1 (ko) 2000-02-24 2007-10-15 워싱톤 유니버시티 Ａβ 펩티드를 격리시키는 인간화 항체
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
ES2437875T3 (es) 2001-04-30 2014-01-14 Eli Lilly And Company Anticuerpos humanizados que reconocen el péptido beta-amiloide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004029629A1 (en) 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
AU2004274390A1 (en) 2003-03-28 2005-03-31 Jacqueline M. Benson Anti-amyloid antibodies, compositions, methods and uses
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US8005620B2 (en) 2003-08-01 2011-08-23 Dna Twopointo Inc. Systems and methods for biopolymer engineering
US20080050357A1 (en) 2003-08-01 2008-02-28 Claes Gustafsson Systems and Methods for Antibody Engineering
WO2005018424A2 (en) 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
TWI355389B (en) 2004-07-30 2012-01-01 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide a
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
JP4980222B2 (ja) 2004-10-05 2012-07-18 ヤンセン アルツハイマー イミュノセラピー 組換えタンパク質製造を改良するための方法および組成物
EP1814917A2 (en) 2004-10-13 2007-08-08 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
PE20061401A1 (es) 2004-12-15 2006-12-23 Neuralab Ltd ANTICUERPOS Aß PARA MEJORAR LA COGNICION
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
CN101213211A (zh) 2005-06-17 2008-07-02 惠氏公司 纯化含Fc区蛋白的方法
WO2007062852A2 (en) 2005-11-30 2007-06-07 Abbott Laboratories ANTI-Aβ GLOBULOMER ANTIBODIES, ANTIGEN-BINDING MOIETIES THEREOF, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, METHODS OF PRODUCING SAID ANTIBODIES, COMPOSITIONS COMPRISING SAID ANTIBODIES, USES OF SAID ANTIBODIES AND METHODS OF USING SAID ANTIBODIES
PE20071002A1 (es) 2005-12-12 2007-11-19 Hoffmann La Roche Anticuerpo anti b4-amilode que contiene asparagina glicosilada en la region variable de vh
NZ571038A (en) 2006-03-30 2011-03-31 Glaxo Group Ltd Antibodies against amyloid-beta peptide
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
AU2007275467B2 (en) 2006-07-14 2013-12-05 Ac Immune S.A. Humanized antibody against amyloid beta
WO2008030251A1 (en) 2006-09-08 2008-03-13 Georgetown University Deglycosylated anti-amyloid beta antibodies
ES2640095T3 (es) 2006-10-02 2017-10-31 Ac Immune S.A. Anticuerpo humanizado contra beta-amiloide
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
SI2436696T1 (sl) 2007-01-05 2017-10-30 University Of Zurich Anti-beta-amiloidno protitelo in načini njegove uporabe
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
KR20100016661A (ko) 2007-04-18 2010-02-12 얀센 알츠하이머 이뮤노테라피 대뇌 아밀로이드 혈관병증의 예방 및 치료
KR20150055103A (ko) 2007-06-12 2015-05-20 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
EP2182983B1 (en) 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
CA2701790A1 (en) 2007-10-05 2009-04-16 Ac Immune S.A. Use of humanized anti-beta-amyloid antibody in ocular diseases
US20100291071A1 (en) 2008-08-01 2010-11-18 Immunas Pharma, Inc. Antibody Specific Binding to A-Beta Oligomer and the Use
CA2702880A1 (en) 2007-10-19 2009-04-23 Immunas Pharma, Inc. Antibody capable of specifically binding to a beta oligomer, and use thereof
CA2705582A1 (en) 2007-11-16 2009-05-22 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
CA2714413C (en) 2008-02-08 2017-01-24 Immunas Pharma, Inc. Antibody capable of binding specifically to ab-oligomer, and use thereof
CA2725666A1 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
US7561973B1 (en) 2008-07-31 2009-07-14 Dna Twopointo, Inc. Methods for determining properties that affect an expression property value of polynucleotides in an expression system
US8126653B2 (en) 2008-07-31 2012-02-28 Dna Twopointo, Inc. Synthetic nucleic acids for expression of encoded proteins
AU2009268585C1 (en) 2008-07-08 2014-10-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
JP2011527338A (ja) 2008-07-09 2011-10-27 ユニバーシティー オブ チューリッヒ 神経新生を促進する方法
WO2010030203A1 (en) 2008-09-09 2010-03-18 Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2010119704A1 (en) 2009-04-17 2010-10-21 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
US8512677B2 (en) 2009-04-27 2013-08-20 Case Western Reserve University Pyro-glutamate Aβ targeting agents
CN102458459A (zh) 2009-05-01 2012-05-16 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
WO2011000095A1 (en) 2009-07-02 2011-01-06 Angiochem Inc. Multimeric peptide conjugates and uses thereof
US8858949B2 (en) 2009-08-06 2014-10-14 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
US8617549B2 (en) 2009-09-11 2013-12-31 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Bispecific nanobodies as a therapeutic for alzheimer's disease
TW201144437A (en) 2010-03-03 2011-12-16 Boehringer Ingelheim Int A-beta binding polypeptides
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
US9320793B2 (en) 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
WO2012021475A2 (en) 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
PL3339323T3 (pl) 2010-08-12 2020-05-18 Eli Lilly And Company Przeciwciała przeciwko peptydowi N3pGlu amyloidu beta i ich zastosowania
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
US9534016B2 (en) 2011-11-28 2017-01-03 Buck Institute For Research On Aging Netrin loop peptide mimetics and uses thereof
JP6342333B2 (ja) * 2012-01-27 2018-06-13 プロセナ バイオサイエンシーズ リミテッド α−シヌクレインを認識するヒト化抗体
ITRM20120383A1 (it) 2012-03-20 2013-09-21 Uni Degli Studi Di Milano B Icocca Metodo e kit per la rivelazione di anticorpi.
JP2015526409A (ja) 2012-07-03 2015-09-10 ヤンセン・サイエンシズ・アイルランド・ユーシー Ｃ−末端及び中心エピトープａ−ベータ抗体
HK1215673A1 (zh) 2012-12-07 2016-09-09 Biogen International Neuroscience Gmbh 一個使用抗ab抗體減少腦部澱粉蛋白質斑的方法
US20140314741A1 (en) * 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
US9486559B2 (en) 2013-05-07 2016-11-08 Abbott Cardiovascular Systems Inc. Methods of treatment with a bioresorbable scaffold for neurologic drug delivery
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015035190A1 (en) 2013-09-05 2015-03-12 Cornell University Gene therapy for alzheimer's and other neurodegenerative diseases and conditions
KR102496162B1 (ko) * 2013-12-20 2023-02-09 뉴리뮨 홀딩 아게 트랜스티레틴(ttr) 아밀로이드증의 항체-기반의 치료 및 이를 위한 인간-유래의 항체
ES2873248T3 (es) 2014-02-08 2021-11-03 Hoffmann La Roche Métodos para tratar la enfermedad de Alzheimer
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
CA2949182A1 (en) 2014-05-16 2015-11-19 Universitat Autonoma De Barcelona Single chain variable fragment (scfv) elongation mutants
US20160002343A1 (en) * 2014-06-11 2016-01-07 Abbvie Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
AU2015286707B2 (en) 2014-07-10 2020-05-21 Bioarctic Neuroscience Ab Improved A beta protofibril binding antibodies
AU2015295441B2 (en) 2014-07-29 2020-05-14 Neurimmune Holding Ag Human-derived anti-huntingtin (HTT) antibodies and uses thereof
WO2016040903A1 (en) 2014-09-11 2016-03-17 Board Of Regents Of The University Of Texas System Detection of misfolded amyloid beta protein
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
US20170363645A1 (en) 2014-12-19 2017-12-21 Probiodrug Ag Novel Method for the Detection of pGlu-Abeta Peptides
WO2016137947A1 (en) 2015-02-24 2016-09-01 Rpeptide, Llc Anti-amyloid-beta antibodies
IL256579B2 (en) 2015-07-16 2023-03-01 Probiodrug Ag Human antibodies
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
JOP20170004B1 (ar) 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
CN114113625A (zh) 2016-01-20 2022-03-01 基因泰克公司 用于阿尔茨海默氏病的高剂量治疗
EP4063858A1 (en) 2016-03-14 2022-09-28 Biogen International Neuroscience GmbH Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins
US11596699B2 (en) 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
AU2017276656A1 (en) 2016-06-07 2018-12-13 Biogen International Neuroscience Gmbh Methods for treating alzheimer's disease
SG11201900123TA (en) 2016-07-19 2019-02-27 Annexon Inc Compositions and methods for treating frontotemporal dementia
BR112019008359A2 (pt) 2016-10-27 2019-10-01 Eisai R&D Man Co Ltd método para tratamento da doença de alzheimer, e, composição farmacêutica.
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
BR112018014281A2 (pt) 2016-11-15 2018-12-18 H Lundbeck As agentes, usos e métodos para o tratamento da sinucleinopatia
WO2018119001A1 (en) 2016-12-19 2018-06-28 Fred Hutchinson Cancer Research Center Peptide-antibody compositions and methods of use thereof
EP3354278A1 (en) 2017-01-31 2018-08-01 Sanofi Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide
WO2018204408A1 (en) 2017-05-02 2018-11-08 Sanford Burnham Prebys Medical Discovery Institute Methods of diagnosing and treating alzheimer's disease
EP3431496A1 (en) 2017-07-19 2019-01-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti- isoasp7 amyloid beta antibodies and uses thereof
IL272773B2 (en) 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical compositions containing anti-beta amyloid antibodies
JP2021502955A (ja) 2017-09-28 2021-02-04 プロセナ・バイオサイエンシズ・リミテッド シヌクレイン病の治療のための投与レジメン
US20190153102A1 (en) 2017-09-28 2019-05-23 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
US20200330592A1 (en) 2017-10-09 2020-10-22 Keith Black Compositions and methods of treating alzheimer's and other amyloid related diseases
WO2019157440A1 (en) 2018-02-09 2019-08-15 The Trustees Of Dartmouth College Chimeric antigen receptors for treatment of neurodegenerative diseases and disorders
KR20210032408A (ko) 2018-07-17 2021-03-24 지앙수 헨그루이 메디슨 컴퍼니 리미티드 항-a베타 항체, 그의 항원-결합 단편 및 그의 적용
JP7541505B2 (ja) 2018-07-24 2024-08-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 アルツハイマー病の治療及び予防方法
EP3836966A4 (en) 2018-08-17 2022-06-08 Ab Studio Inc. CATALYTIC ANTIBODIES AND THEIR METHODS OF USE
AU2019370485A1 (en) 2018-11-02 2021-05-13 Annexon, Inc. Compositions and methods for treating brain injury
KR20210143752A (ko) 2019-02-12 2021-11-29 프로테나 바이오사이언시즈 리미티드 항체-생산 세포 및 기타 면역 세포 상의 cd38 세포 막 분자 및 면역글로불린 경쇄에 대한 단일클론 항체들의 조합을 이용한 al 아밀로이드증의 치료
WO2020193644A1 (en) 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF
CA3176743A1 (en) 2019-04-04 2020-10-08 The Royal Institution For The Advancement Of Learning / Mcgill University Use of a.beta.34 to assess alzheimer's disease progression
JP2022544640A (ja) 2019-06-21 2022-10-20 ユニバーシティ オブ カンザス 脳疾患の治療に有用な組成物および方法
ES2821599A1 (es) 2019-10-24 2021-04-26 Univ Del Pais Vasco / Euskal Herriko Unibertsitatea Compuestos y metodos para el tratamiento de la enfermedad de alzheimer
US20230027014A1 (en) 2019-11-12 2023-01-26 Ambetex Pty Ltd Therapeutic compositions comprising an amyloid beta antibody or vaccine for prevention and treatment of diastolic dysfunction
IL295383A (en) 2020-03-20 2022-10-01 Eisai R&D Man Co Ltd High concentration anti-aß protofibril antibody formulations and methods of use thereof
CN116348487A (zh) * 2020-07-23 2023-06-27 欧萨尔普罗席纳有限公司 抗淀粉样β抗体

Also Published As

Publication number Publication date
PH12023550178A1 (en) 2023-12-04
US11434283B2 (en) 2022-09-06
US20220049009A1 (en) 2022-02-17
CL2024000953A1 (es) 2024-07-26
US20230331828A1 (en) 2023-10-19
MX2023000949A (es) 2023-02-22
US20220041701A1 (en) 2022-02-10
AU2021310926A1 (en) 2023-03-23
US20220041700A1 (en) 2022-02-10
UY39337A (es) 2022-02-25
CA3186614A1 (en) 2022-01-27
CL2025000063A1 (es) 2025-05-16
WO2022020680A1 (en) 2022-01-27
BR112023001061A2 (pt) 2023-04-04
KR20230039734A (ko) 2023-03-21
EP4185612A1 (en) 2023-05-31
CN116348487A (zh) 2023-06-27
US20220242940A1 (en) 2022-08-04
US20220041699A1 (en) 2022-02-10
US20220089762A1 (en) 2022-03-24
US20250179161A1 (en) 2025-06-05
IL300059A (en) 2023-03-01
US11434285B2 (en) 2022-09-06
JP2023535024A (ja) 2023-08-15
TW202216760A (zh) 2022-05-01
US11440953B2 (en) 2022-09-13
EP4185612A4 (en) 2024-12-25
US11434284B2 (en) 2022-09-06

Similar Documents

Publication Publication Date Title
CL2023000216A1 (es) Anticuerpos anti-abeta
MX383464B (es) Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
BR112020002012A8 (pt) Anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
CO2020005981A2 (es) Anticuerpos anti-tau y uso de los mismos
CO2021001893A2 (es) Anticuerpos anti-gdf15, composiciones y métodos de uso
BR112018071307A2 (pt) anticorpos agonistas que ligam cd40 humana e usos dos mesmos
CL2019000334A1 (es) Nuevos conjugados de anticuerpo y usos de los mismos (divisional solicitud 201502357)
CL2021003343A1 (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3.
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
BR112019012354A2 (pt) anticorpos apenas de cadeia pesada anti-bcma
BR112017005517A2 (pt) anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
CR20170600A (es) Anticuerpos del factor x1 y métodos de uso
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
CL2020001334A1 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos. (divisional solicitud 201900999)
MX2023009874A (es) Anticuerpos anti-psma y estructuras car-t.
CL2021003228A1 (es) Compuestos tricíclicos y su uso
BR112019010034A2 (pt) fator viii alvejado de hemácia e método de uso do mesmo
CL2025000151A1 (es) Anticuerpos tmem219 y usos terapéuticos de los mismos
CO2021014748A2 (es) Conjugado de anticuerpo anti-bcma, composiciones que lo comprenden, y métodos de fabricación y uso del mismo
BR112022012522A2 (pt) Proteínas de ligação de tgf-beta-rii
MX2021003888A (es) Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares.
AR123050A1 (es) ANTICUERPOS ANTI-Ab